Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle

Growth Hormone and IGF Research

Volumn 20, Issue 5, 2010, Pages 372-379

  Pöllänen, Eija ^a   Ronkainen, Paula H A ^a   Horttanainen, Mia ^a   Takala, Timo ^b   Puolakka, Jukka ^c   Suominen, Harri ^a   Sipilä, Sarianna ^a   Kovanen, Vuokko ^a  

^a UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Central Finland Central Hospital   (Finland)

Author keywords

Estradiol; Hormone replacement therapy; IGF 1 signaling; Muscle; Norethisterone acetate; Postmenopausal women

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TESTOSTERONE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1;

ADULT; ANIMAL CELL; AR GENE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOXO3 GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IGF 1 GENE; IGF 1EC GENE; MOUSE; MTOR GENE; MUSCLE MASS; MYOTUBE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RNA SPLICING; SKELETAL MUSCLE; UPREGULATION;

ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; NORETHINDRONE; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SKP CULLIN F-BOX PROTEIN LIGASES; TESTOSTERONE; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 77957120407     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.07.003     Document Type: Article

References (56)

1. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., Schwartz R.J. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 1995, 270:12109-12116.
2. Sheffield-Moore M., Urban R.J. An overview of the endocrinology of skeletal muscle. Trends Endocrinol. Metab. 2004, 15:110-115.
3. Lluis F., Perdiguero E., Nebreda A.R., Munoz-Canoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 2006, 16:36-44.
4. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3:1014-1019.
5. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
6. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
7. Hajduch E., Litherland G.J., Hundal H.S. Protein kinase B (PKB/Akt)-a key regulator of glucose transport?. FEBS Lett. 2001, 492:199-203.
8. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
9. Nave B.T., Ouwens M., Withers D.J., Alessi D.R., Shepherd P.R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 1999, 344(Pt 2):427-431.
10. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3:1009-1013.
11. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 2004, 14:395-403.
12. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., Goldberg A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
13. Fan W., Yanase T., Morinaga H., Okabe T., Nomura M., Daitoku H., Fukamizu A., Kato S., Takayanagi R., Nawata H. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J. Biol. Chem. 2007, 282:7329-7338.
14. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
15. Taaffe D.R., Sipila S., Cheng S., Puolakka J., Toivanen J., Suominen H. The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clin. Physiol. Funct. Imaging 2005, 25:297-304.
16. Cheng S., Sipilä S., Taaffe D.R., Puolakka J., Suominen H. Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone 2002, 31:126-135.
17. Sipila S., Taaffe D.R., Cheng S., Puolakka J., Toivanen J., Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clin. Sci. (Lond) 2001, 101:147-157.
18. Ronkainen P.H., Kovanen V., Alen M., Pöllänen E., Palonen E.M., Ankarberg-Lindgren C., Hamalainen E., Turpeinen U., Kujala U.M., Puolakka J., Kaprio J., Sipilä S. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J. Appl. Physiol. 2009, 107:25-33.
19. Phillips S.K., Rook K.M., Siddle N.C., Bruce S.A., Woledge R.C. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin. Sci. (Lond) 1993, 84:95-98.
20. Greeves J.P., Cable N.T., Reilly T., Kingsland C. Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. Clin. Sci. (Lond) 1999, 97:79-84.
21. Sorensen M.B., Rosenfalck A.M., Hojgaard L., Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes. Res. 2001, 9:622-626.
22. Dobs A.S., Nguyen T., Pace C., Roberts C.P. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J. Clin. Endocrinol. Metab. 2002, 87:1509-1516.
23. Skelton D.A., Phillips S.K., Bruce S.A., Naylor C.H., Woledge R.C. Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. Clin. Sci. (Lond) 1999, 96:357-364.
24. Vasconsuelo A., Milanesi L., Boland R. 17Beta-estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway. J. Endocrinol. 2008, 196:385-397.
25. Pöllänen E., Ronkainen P.H., Suominen H., Takala T., Koskinen S., Puolakka J., Sipilä S., Kovanen V. Muscular transcriptome in postmenopausal women with or without hormone replacement. Rejuvenation Res. 2007, 10:485-500.
26. Kopernik G., Shoham Z. Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. Fertil. Steril. 2004, 81:1458-1477.
27. E. Pöllänen, V. Fey, T. Törmäkangas, P.H.A. Ronkainen, D. Taaffe, T. Takala, S. Koskinen, S. Cheng, U.M. Kujala, J. Puolakka, H. Suominen, V. Kovanen, S. Sipilä, Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle, Age (Dordr). 2010 Apr 13. [Epub ahead of print], doi:10.1007/s11357-010-9140-1.
28. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
29. Hassager C., Christiansen C. Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women. Metabolism 1989, 38:662-665.
30. Jensen J., Christiansen C., Rodbro P. Oestrogen-progestogen replacement therapy changes body composition in early post-menopausal women. Maturitas 1986, 8:209-216.
31. Walker R.J., Lewis-Barned N.J., Sutherland W.H., Goulding A., Edwards E.A., de Jong S.A., Gold E., Walker H.L. The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 2001, 8:27-32.
32. Davis S.R., Walker K.Z., Strauss B.J. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 2000, 7:395-401.
33. Tanko L.B., Movsesyan L., Svendsen O.L., Christiansen C. The effect of hormone replacement therapy on appendicular lean tissue mass in early postmenopausal women. Menopause 2002, 9:117-121.
34. Kenny A.M., Kleppinger A., Wang Y., Prestwood K.M. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women. J. Am. Geriatr. Soc. 2005, 53:1973-1977.
35. Thorneycroft I.H., Lindsay R., Pickar J.H. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. Am. J. Obstet. Gynecol. 2007, 197:137.e1-137.e7.
36. Goldspink G., Harridge S.D. Growth factors and muscle ageing. Exp. Gerontol. 2004, 39:1433-1438.
37. Matheny R.W., Nindl B.C., Adamo M.L. Minireview: mechano-growth factor: a putative product of IGF-1 gene expression involved in tissue repair and regeneration. Endocrinol. 2010, 151:865-875.
38. Enns D.L., Tiidus P.M. Estrogen influences satellite cell activation and proliferation following downhill running in rats. J. Appl. Physiol. 2008, 104:347-353.
39. Kamanga-Sollo E., Pampusch M.S., Xi G., White M.E., Hathaway M.R., Dayton W.R. IGF-I mRNA levels in bovine satellite cell cultures: effects of fusion and anabolic steroid treatment. J. Cell. Physiol. 2004, 201:181-189.
40. Kamanga-Sollo E., White M.E., Hathaway M.R., Chung K.Y., Johnson B.J., Dayton W.R. Roles of IGF-I and the estrogen, androgen and IGF-I receptors in estradiol-17beta- and trenbolone acetate-stimulated proliferation of cultured bovine satellite cells. Domest. Anim. Endocrinol. 2008, 35:88-97.
41. Dieli-Conwright C.M., Spektor T.M., Rice J.C., Sattler F.R., Schroeder E.T. Influence of hormone replacement therapy on eccentric exercise induced myogenic gene expression in postmenopausal women. J. Appl. Physiol. 2009, 107:1381-1388.
42. Enns D.L., Iqbal S., Tiidus P.M. Oestrogen receptors mediate oestrogen-induced increases in post-exercise rat skeletal muscle satellite cells. Acta Physiol. (Oxf) 2008, 194:81-93.
43. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15:6541-6551.
44. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
45. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
46. Alisi A., Spaziani A., Anticoli S., Ghidinelli M., Balsano C. PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways. Cell. Signal. 2008, 20:534-542.
47. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 2005, 37:1974-1984.
48. Jaffer S., Shynlova O., Lye S. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. Endocrinology 2009, 150:4672-4680.
49. Sobolewska A., Gajewska M., Zarzynska J., Gajkowska B., Motyl T. IGF-I, EGF, and sex steroids regulate autophagy in bovine mammary epithelial cells via the mTOR pathway. Eur. J. Cell Biol. 2009, 88:117-130.
50. Harridge S.D. Plasticity of human skeletal muscle: gene expression to in vivo function. Exp. Physiol. 2007, 92:783-797.
51. Philippou A., Papageorgiou E., Bogdanis G., Halapas A., Sourla A., Maridaki M., Pissimissis N., Koutsilieris M. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo 2009, 23:567-575.
52. Gentile M.A., Nantermet P.V., Vogel R.L., Phillips R., Holder D., Hodor P., Cheng C., Dai H., Freedman L.P., Ray W.J. Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J. Mol. Endocrinol. 2010, 44:55-73.
53. Murphy L.J., Murphy L.C., Friesen H.G. Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol. Endocrinol. 1987, 1:445-450.
54. Chesik D., De Keyser J. Progesterone and dexamethasone differentially regulate the IGF-system in glial cells. Neurosci. Lett. 2010, 468:178-182.
55. Ferrando A.A., Sheffield-Moore M., Yeckel C.W., Gilkison C., Jiang J., Achacosa A., Lieberman S.A., Tipton K., Wolfe R.R., Urban R.J. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E601-7.
56. Hewitt S.C., Collins J., Grissom S., Deroo B., Korach K.S. Global uterine genomics in vivo: microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. Mol. Endocrinol. 2005, 19:657-668.